Sessile serrated adenomas (SSAs) are premalignant lesions driven by the BRAFV600E mutation to give rise to colorectal cancers (CRCs). They are often missed during white light colonoscopy because of their subtle appearance. Previously, a fluorescently labeled 7mer peptide KCCFPAQ was shown to detect SSAs in vivo. We aim to identify the target of this peptide.
Results:
Peroxiredoxin-1 (Prdx1) was identified as the binding partner of the peptide ligand. In vitro binding assays and immunofluorescence staining of human colon specimens ex vivo supported this result. Prdx1 was overexpressed on the membrane of cells with the BRAFV600E mutation, and this effect was dependent on oxidative stress. RKO cells harboring the BRAFV600E mutation and human SSA specimens showed higher oxidative stress as well as elevated levels of Prdx1 on the cell membrane.
Innovation and Conclusion:
These results suggest that Prdx1 is overexpressed on the cell surface in the presence of oxidative stress and can serve as an imaging biomarker for in vivo detection of SSAs. Antioxid. Redox Signal. 36, 39–56.
Get full access to this article
View all access options for this article.
References
1.
ArnoldM, SierraMS, LaversanneM, SoerjomataramI, JemalA, and BrayF. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 66: 683–691, 2017.
2.
BabkoffA, Cohen-KfirE, AharonH, RonenD, RosenbergM, WienerR, and RavidS. A direct interaction between survivin and myosin II is required for cytokinesis. J Cell Sci, 132: jcs233130, 2019.
3.
BaruaP, AhnSB, MohamedaliA, and LiuF. Improved sensitivity in cell surface protein detection by combining chemical labeling with mechanical lysis in a colorectal cancer cell model. Biotechnol Lett, 42: 683–695, 2020.
4.
BaxterNN, GoldwasserMA, PaszatLF, SaskinR, UrbachDR, and RabeneckL. Association of colonoscopy and death from colorectal cancer. Ann Intern Med, 150: 1–8, 2009.
5.
CaiCY, ZhaiLL, WuY, and TangZG. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer. Eur J Surg Oncol, 41: 228–235, 2015.
6.
ChuKL, LewQJ, RajasegaranV, KungJT, ZhengL, YangQ, ShawR, CheongN, LiouY-C, and ChaoS-H. Regulation of PRDX1 peroxidase activity by Pin1. Cell Cycle (Georgetown, Tex.), 12: 944–952, 2013.
7.
Dalla RizzaJ, RandallLM, SantosJ, Ferrer-SuetaG, and DenicolaA. Differential parameters between cytosolic 2-Cys peroxiredoxins, PRDX1 and PRDX2. Protein Sci, 28: 191–201, 2019.
DameMK, JiangY, AppelmanHD, CopleyKD, McClintockSD, AslamMN, AttiliD, ElmunzerBJ, BrennerDE, VaraniJ, and TurgeonDK. Human colonic crypts in culture: segregation of immunochemical markers in normal versus adenoma-derived. Lab Invest, 94: 222–234, 2014.
DingC, FanX, and WuG. Peroxiredoxin 1—an antioxidant enzyme in cancer. J Cell Mol Med, 21: 193–202, 2017.
12.
ErichsenR, BaronJA, Hamilton-DutoitSJ, SnoverDC, TorlakovicEE, PedersenL, FrøslevT, VybergM, HamiltonSR, and SørensenHT. Increased risk of colorectal cancer development among patients with serrated polyps. Gastroenterology, 150: 895–902.e5, 2016.
13.
FearonER. Molecular genetics of colorectal cancer. Annu Rev Pathol, 6: 479–507, 2011.
14.
FuX and ZhangX. BRAF mutation as a potential marker to identify the proximal colon serrated polyps with malignant potential. Int J Clin Exp Pathol, 7: 7319–7322, 2014.
15.
GennaA, LapetinaS, LukicN, TwafraS, MeirsonT, SharmaVP, and CondeelisJS, Gil-HennH. Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol, 217: 375–395, 2018.
16.
GhoshD, FunkCC, CaballeroJ, ShahN, RouleauK, EarlsJC, SoroceanuL, FoltzG, CobbsCS, PriceND, and HoodL. A cell-surface membrane protein signature for glioblastoma. Cell Syst, 4: 516–529.e7, 2017.
17.
GongF, HouG, LiuH, and ZhangM. Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. Med Oncol, 32: 455, 2015.
18.
HinoiT, AkyolA, TheisenBK, FergusonDO, GreensonJK, WilliamsBO, ChoKR, and FearonER. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res, 67: 9721–9730, 2007.
19.
InJG, Foulke-AbelJ, EstesMK, ZachosNC, KovbasnjukO, and DonowitzM. Human mini-guts: new insights into intestinal physiology and host-pathogen interactions. Nat Rev Gastroenterol Hepatol, 13: 633–642, 2016.
20.
JiangH, WuL, MishraM, ChawsheenHA, and WeiQ. Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy. Am J Cancer Res, 4: 445–460, 2014.
21.
JiangL, XiaoX, RenJ, TangY, WengH, YangQ, WuM, and TangW. Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system. PLoS One, 9: e98764, 2014.
22.
JoshiBP, DaiZ, GaoZ, LeeJH, GhimireN, ChenJ, PrabhuA, WamstekerEJ, KwonRS, EltaGH, StoffelEM, PantA, KaltenbachT, SoetiknoRM, AppelmanHD, KuickR, TurgeonDK, and WangTD. Detection of sessile serrated adenomas in the proximal colon using wide-field fluorescence endoscopy. Gastroenterology, 152: 1002–1013.e9, 2017.
23.
JoshiBP, DuanX, KwonRS, PirakaC, ElmunzerBJ, LuS, RabinskyEF, BeerDG, AppelmanHD, OwensSR, KuickR, DoguchiN, TurgeonDK, and WangTD. Multimodal endoscope can quantify wide-field fluorescence detection of Barrett's neoplasia. Endoscopy, 48: A1–a13, 2016.
24.
JoshiBP, LiuZ, ElahiSF, AppelmanHD, and WangTD. Near-infrared-labeled peptide multimer functions as phage mimic for high affinity, specific targeting of colonic adenomas in vivo (with videos). Gastrointest Endosc 76: 1197–1206.e, 1–e5, 2012.
25.
KahiCJ, HewettDG, NortonDL, EckertGJ, and RexDK. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol, 9: 42–46, 2011.
26.
KimJH, BognerPN, BaekSH, RamnathN, LiangP, KimHR, AndrewsC, and ParkYM. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res, 14: 2326–2333, 2008.
27.
KimYJ, LeeWS, IpC, ChaeHZ, ParkEM, and ParkYM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res, 66: 7136–7142, 2006.
28.
LapetinaS and Gil-HennH. A guide to simple, direct, and quantitative in vitro binding assays. J Biol Methods, 4: e62, 2017.
29.
LeggettB and WhitehallV. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology, 138: 2088–2100, 2010.
30.
LiS, HuX, YeM, and ZhuX. The prognostic values of the peroxiredoxins family in ovarian cancer. Biosci Rep, 38: BSR20180667, 2018.
31.
MiyoshiH and StappenbeckTS. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat Protoc, 8: 2471–2482, 2013.
32.
MullenL, HanschmannEM, LilligCH, HerzenbergLA, and GhezziP. Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion. Mol Med, 21: 98–108, 2015.
33.
NeumannCA, CaoJ, and ManevichY. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle, 8: 4072–4078, 2009.
34.
NishiharaR, WuK, LochheadP, MorikawaT, LiaoX, QianZR, InamuraK, KimSA, KuchibaA, YamauchiM, ImamuraY, WillettWC, RosnerBA, FuchsCS, GiovannucciE, OginoS, and ChanAT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med, 369: 1095–1105, 2013.
35.
PatilDT, ShadrachBL, RybickiLA, LeachBH, and PaiRK. Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. Mod Pathol, 25: 1423–1431, 2012.
36.
PaulFE, HospF, and SelbachM. Analyzing protein-protein interactions by quantitative mass spectrometry. Methods, 54: 387–395, 2011.
37.
PayneSR, ChurchTR, WandellM, RöschT, OsbornN, SnoverD, DayRW, RansohoffDF, and RexDK. Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. Clin Gastroenterol Hepatol, 12: 1119–1126, 2014.
38.
PhuchareonJ, McCormickF, EiseleDW, and TetsuO. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A, 112: E3855–E3863, 2015.
39.
PopracP, JomovaK, SimunkovaM, KollarV, RhodesCJ, and ValkoM. Targeting free radicals in oxidative stress-related human diseases. Trends Pharmacol Sci, 38: 592–607, 2017.
40.
RavenhillBJ, SodayL, HoughtonJ, AntrobusR, and WeekesMP. Comprehensive cell surface proteomics defines markers of classical, intermediate and non-classical monocytes. Sci Rep, 10: 4560, 2020.
41.
RenP, YeH, DaiL, LiuM, LiuX, ChaiY, ShaoQ, LiY, LeiN, PengB, YaoW, and ZhangJ. Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma. Oncol Rep, 30: 2297–2303, 2013.
42.
RexDK, AhnenDJ, BaronJA, BattsKP, BurkeCA, BurtRW, GoldblumJR, GuillemJG, KahiCJ, KaladyMF, O'BrienMJ, OdzeRD, OginoS, ParryS, SnoverDC, TorlakovicEE, WisePE, YoungJ, and ChurchJ. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol, 107: 1315–1329; quiz 1314, 1330, 2012.
43.
RexDK, BolandCR, DominitzJA, GiardielloFM, JohnsonDA, KaltenbachT, LevinTR, LiebermanD, and RobertsonDJ. Colorectal Cancer Screening: recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 153: 307–323, 2017.
44.
RhoJH, QinS, WangJY, and RoehrlMH. Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res, 7: 2959–2972, 2008.
45.
SheuJJ, GuanB, TsaiFJ, HsiaoEY, ChenCM, SerucaR, WangTL, and ShihIM. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am J Pathol, 180: 1179–1188, 2012.
46.
SiegelRL, MillerKD, and JemalA. Cancer statistics, 2019. CA Cancer J Clin, 69: 7–34, 2019.
47.
SinghH, NugentZ, DemersAA, KliewerEV, MahmudSM, and BernsteinCN. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology, 139: 1128–1137, 2010.
48.
SunYL, CaiJQ, LiuF, BiXY, ZhouLP, and ZhaoXH. Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer. World J Gastroenterol, 21: 10840–10852, 2015.
49.
SvendsenA, VerhoeffJJ, ImmervollH, BrøggerJC, KmiecikJ, PoliA, NetlandIA, PrestegardenL, PlanagumàJ, TorsvikA, KjersemAB, SakariassenP, HeggdalJI, Van FurthWR, BjerkvigR, Lund-JohansenM, EngerP, FelsbergJ, BronsNH, TronstadKJ, WahaA, and ChekenyaM. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol, 122: 495–510, 2011.
TsaiYH, CzerwinskiM, WuA, DameMK, AttiliD, HillE, ColacinoJA, NowackiLM, ShroyerNF, HigginsPDR, KaoJY, and SpenceJR. A Method for Cryogenic Preservation of Human Biopsy Specimens and Subsequent Organoid Culture. Cell Mol Gastroenterol Hepatol, 6: 218–222.e7, 2018.
52.
Turner-IveyB, ManevichY, SchulteJ, Kistner-GriffinE, Jezierska-DrutelA, LiuY, and NeumannCA. Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer. Oncogene, 32: 5302–5314, 2013.
53.
WangX, HeS, SunJM, DelcuveGP, and DavieJR. Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells. Mol Biol Cell, 21: 2987–2995, 2010.
54.
WojdylaK, CollierAJ, FabianC, NisiPS, BigginsL, OxleyD, and Rugg-GunnPJ. Cell-surface proteomics identifies differences in signaling and adhesion protein expression between naive and primed human pluripotent stem cells. Stem Cell Reports, 14: 972–988, 2020.
55.
WooHA, YimSH, ShinDH, KangD, YuDY, and RheeSG. Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell, 140: 517–528, 2010.
56.
XingWM, YuanTJ, XuJD, GuLL, LiangP, and LuH. Proteomic identification of mitochondrial targets involved in andrographolide sodium bisulfite-induced nephrotoxicity in a rat model. Environ Toxicol Pharmacol, 40: 592–599, 2015.
57.
XueX, RamakrishnanSK, WeiszK, TrinerD, XieL, AttiliD, PantA, GyőrffyB, ZhanM, Carter-SuC, HardimanKM, WangTD, DameMK, VaraniJ, BrennerD, FearonER, and ShahYM. Iron Uptake via DMT1 integrates cell cycle with JAK-STAT3 signaling to promote colorectal tumorigenesis. Cell Metab, 24: 447–461, 2016.
58.
XueY, JohnsonR, DesmetM, SnyderPW, and FleetJC. Generation of a transgenic mouse for colorectal cancer research with intestinal cre expression limited to the large intestine. Mol Cancer Res, 8: 1095–1104, 2010.
59.
YamadaM, SakamotoT, OtakeY, NakajimaT, KuchibaA, TaniguchiH, SekineS, KushimaR, RamberanH, Parra-BlancoA, FujiiT, MatsudaT, and SaitoY. Investigating endoscopic features of sessile serrated adenomas/polyps by using narrow-band imaging with optical magnification. Gastrointest Endosc, 82: 108–117, 2015.
60.
YangH, VillaniRM, WangH, SimpsonMJ, RobertsMS, TangM, and LiangX. The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res, 37: 266, 2018.
61.
YuiS, NakamuraT, SatoT, NemotoY, MizutaniT, ZhengX, IchinoseS, NagaishiT, OkamotoR, TsuchiyaK, CleversH, and WatanabeM. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5⁺ stem cell. Nat Med, 18: 618–623, 2012.
62.
ZachosNC, KovbasnjukO, Foulke-AbelJ, InJ, BluttSE, de JongeHR, EstesMK, and DonowitzM. Human enteroids/colonoids and intestinal organoids functionally recapitulate normal intestinal physiology and pathophysiology. J Biol Chem, 291: 3759–3766, 2016.
63.
ZhengMJ, WangJ, WangHM, GaoLL, LiX, ZhangWC, GouR, GuoQ, NieX, LiuJJ, and LinB. Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell. Onco Targets Ther, 11: 7745–7761, 2018.
64.
ZhouJ, ShenW, HeX, QianJ, LiuS, and YuG. Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis. Int J Clin Exp Pathol, 8: 9863–9874, 2015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
